Jinxin Fertility Group Limited (JXFGF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Jinxin Fertility Group Limited (JXFGF) with AI Score 49/100 (Weak). Jinxin Fertility Group Limited provides assisted reproductive services (ARS) in China and the United States. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Jinxin Fertility Group Limited (JXFGF) Healthcare & Pipeline Overview
Jinxin Fertility Group Limited, operating in the healthcare sector, provides assisted reproductive services in China and the U.S., focusing on artificial insemination and IVF technologies. With a presence in both markets, the company offers comprehensive services including nutrition guidance and psychological counseling, positioning itself in the growing fertility treatment market.
Investment Thesis
Jinxin Fertility Group Limited presents a mixed investment case. The company operates in a sector with increasing demand, driven by factors such as delayed parenthood and rising infertility rates. However, its negative P/E ratio of -5.73 and a profit margin of -35.6% raise concerns about its current profitability. The company's gross margin of 34.2% indicates some ability to generate revenue over direct costs. Growth catalysts include expanding its services and geographic reach within China and the U.S. Potential risks include regulatory changes in the healthcare sector and competition from other fertility clinics. Investors should closely monitor the company's path to profitability and its ability to capitalize on growth opportunities in the ARS market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.78B reflects the company's current valuation in the market.
- P/E Ratio of -5.73 indicates the company is currently not profitable.
- Profit Margin of -35.6% shows significant losses relative to revenue.
- Gross Margin of 34.2% demonstrates the company's ability to generate profit from its services before operating expenses.
- Beta of 0.94 suggests the stock's volatility is slightly lower than the market average.
Competitors & Peers
Strengths
- Presence in both China and the United States.
- Comprehensive range of ARS services.
- Integration of traditional Chinese medicine.
- Holistic patient care approach.
Weaknesses
- Negative profit margin.
- Reliance on regulatory approvals.
- Competition from established players.
- Exposure to economic fluctuations.
Catalysts
- Upcoming: Expansion of clinic network in China to meet growing demand for ARS.
- Ongoing: Development and implementation of innovative ARS technologies.
- Ongoing: Strategic partnerships with research institutions and technology providers.
- Ongoing: Marketing efforts to attract international patients seeking fertility treatments.
Risks
- Potential: Regulatory changes in the healthcare sector affecting ARS practices.
- Potential: Increased competition from other fertility clinics in China and the U.S.
- Potential: Economic downturns impacting patient affordability and demand for ARS.
- Ongoing: Negative profit margin and financial losses.
- Ongoing: Risks associated with operating on the OTC market, including limited liquidity and disclosure.
Growth Opportunities
- Expansion within China: China's large population and evolving family planning policies present a significant growth opportunity for Jinxin Fertility. By expanding its network of clinics in underserved regions and offering advanced ARS technologies, the company can tap into a growing market. The potential market size for ARS in China is estimated to reach billions of dollars in the coming years, driven by increasing awareness and disposable incomes. Timeline: Ongoing.
- Strategic acquisitions and partnerships: Jinxin Fertility can pursue strategic acquisitions and partnerships to expand its service offerings and geographic reach. Collaborating with research institutions and technology providers can enhance its capabilities in areas such as genetic screening and personalized medicine. This strategy can accelerate growth and create synergies within the company's existing operations. Timeline: Ongoing.
- Development of innovative ARS technologies: Investing in research and development to develop innovative ARS technologies can provide Jinxin Fertility with a competitive edge. This includes advancements in IVF techniques, genetic testing, and fertility preservation methods. By offering cutting-edge solutions, the company can attract patients seeking the most advanced treatments available. Timeline: Ongoing.
- Increased focus on international patients: Jinxin Fertility can attract international patients seeking high-quality ARS services at competitive prices. By marketing its services to patients in regions with limited access to advanced fertility treatments, the company can expand its customer base and revenue streams. This strategy requires establishing partnerships with international healthcare providers and offering comprehensive support services to international patients. Timeline: Ongoing.
- Leveraging digital health solutions: Implementing digital health solutions, such as telemedicine and online patient portals, can improve access to care and enhance the patient experience. These technologies can streamline the consultation process, provide remote monitoring, and facilitate communication between patients and healthcare providers. By embracing digital health, Jinxin Fertility can improve efficiency and attract tech-savvy patients. Timeline: Ongoing.
Opportunities
- Expansion into underserved regions in China.
- Strategic acquisitions and partnerships.
- Development of innovative ARS technologies.
- Increased focus on international patients.
Threats
- Regulatory changes in the healthcare sector.
- Competition from other fertility clinics.
- Economic downturns affecting patient affordability.
- Technological advancements rendering existing services obsolete.
Competitive Advantages
- Established presence in both China and the United States.
- Comprehensive range of assisted reproductive services.
- Integration of traditional Chinese medicine with modern fertility treatments.
- Focus on providing holistic care to patients.
About JXFGF
Founded in 2003 and headquartered in Chengdu, China, Jinxin Fertility Group Limited is an investment holding company specializing in assisted reproductive services (ARS). The company operates in both China and the United States, providing a range of fertility treatment options. Its core offerings include artificial insemination, utilizing either husband's sperm or donor sperm, and in vitro fertilization (IVF) technology, which encompasses conventional IVF and intracytoplasmic sperm injection (ICSI). Beyond these primary treatments, Jinxin Fertility offers supportive services such as nutrition guidance, traditional Chinese medicine treatments, and psychological counseling, aiming to provide holistic care to patients. The company also extends its services to gynecology, urology, internal medicine, ambulatory surgery center facilities, and ancillary medical services. Furthermore, Jinxin Fertility engages in pre-implantation genetic screening testing, investment management, management consultancy, and real estate development and operation, diversifying its revenue streams within and beyond the healthcare sector. With over 3,198 employees, Jinxin Fertility aims to address the increasing demand for fertility solutions in its key markets.
What They Do
- Provides artificial insemination services using husband's or donor sperm.
- Offers in vitro fertilization (IVF) technology, including conventional IVF and ICSI.
- Provides nutrition guidance to support assisted reproductive services.
- Offers traditional Chinese medicine treatments.
- Provides psychological counseling to patients undergoing ARS.
- Offers management services for medical facilities.
- Provides medical services in gynecology, urology, and internal medicine.
- Offers pre-implantation genetic screening testing services.
Business Model
- Generates revenue through assisted reproductive services, including artificial insemination and IVF.
- Earns fees from related services such as nutrition guidance, Chinese medicine treatment, and psychological counseling.
- Receives income from management services provided to medical facilities.
- Derives revenue from pre-implantation genetic screening testing services.
Industry Context
Jinxin Fertility Group Limited operates within the assisted reproductive services (ARS) industry, a segment of the healthcare sector experiencing growth due to rising infertility rates and delayed parenthood. The market is competitive, with various clinics and hospitals offering similar services. Trends include technological advancements in IVF and genetic screening, as well as increasing demand for personalized treatment plans. Jinxin Fertility competes with other players in China and the U.S., navigating regulatory landscapes and striving to differentiate through service quality and technology adoption. Competitors include GGNDF (Genea Biomedx), GNNDY (The Cooper Companies Inc).
Key Customers
- Individuals and couples seeking fertility treatments.
- Patients requiring gynecological, urological, or internal medicine services.
- Medical facilities seeking management services.
- International patients seeking ARS services.
Financials
Chart & Info
Jinxin Fertility Group Limited (JXFGF) stock price: Price data unavailable
Latest News
No recent news available for JXFGF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for JXFGF.
Price Targets
Wall Street price target analysis for JXFGF.
MoonshotScore
What does this score mean?
The MoonshotScore rates JXFGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Yang Dong
Unknown
Information on Yang Dong's background is not available in the provided data. Without further information, a detailed profile cannot be created. Yang Dong currently manages 3198 employees at Jinxin Fertility Group Limited.
Track Record: Information on Yang Dong's track record is not available in the provided data. Without further information, a detailed analysis of their achievements and strategic decisions cannot be provided.
JXFGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Jinxin Fertility Group Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, are undergoing financial distress, or are subject to regulatory scrutiny. Investing in OTC Other stocks carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity. These stocks are not subject to the same listing requirements as those traded on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or scams.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Monitor trading volume and price activity.
- Consult with a qualified financial advisor.
- Understand the risks associated with OTC investments.
- Established operating history since 2003.
- Presence in both China and the United States.
- Employee count of over 3,000.
- Focus on providing comprehensive ARS services.
Jinxin Fertility Group Limited Stock: Key Questions Answered
What does Jinxin Fertility Group Limited do?
Jinxin Fertility Group Limited is an investment holding company that provides assisted reproductive services (ARS) in China and the United States. The company offers a range of fertility treatments, including artificial insemination and in vitro fertilization (IVF). It also provides related services such as nutrition guidance, traditional Chinese medicine treatments, and psychological counseling. Jinxin Fertility operates medical facilities and offers pre-implantation genetic screening testing services, aiming to provide comprehensive fertility solutions to its patients.
What do analysts say about JXFGF stock?
Analyst information for JXFGF is not available in the provided data. Without analyst ratings or price targets, it is difficult to assess market sentiment or valuation considerations. Investors should conduct their own research and consult with financial advisors before making investment decisions. Key metrics to consider include the company's financial performance, growth prospects, and competitive landscape.
What are the main risks for JXFGF?
Jinxin Fertility Group Limited faces several risks, including regulatory changes in the healthcare sector, increased competition from other fertility clinics, and economic downturns affecting patient affordability. The company's negative profit margin and financial losses pose a significant challenge. Operating on the OTC market carries additional risks, such as limited liquidity and disclosure. Investors should carefully consider these risks before investing in JXFGF.
What are the key factors to evaluate for JXFGF?
Jinxin Fertility Group Limited (JXFGF) currently holds an AI score of 49/100, indicating low score. Key strength: Presence in both China and the United States.. Primary risk to monitor: Potential: Regulatory changes in the healthcare sector affecting ARS practices.. This is not financial advice.
How frequently does JXFGF data refresh on this page?
JXFGF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven JXFGF's recent stock price performance?
Recent price movement in Jinxin Fertility Group Limited (JXFGF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Presence in both China and the United States.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider JXFGF overvalued or undervalued right now?
Determining whether Jinxin Fertility Group Limited (JXFGF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying JXFGF?
Before investing in Jinxin Fertility Group Limited (JXFGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Some information, particularly regarding CEO background and analyst opinions, is not available in the provided data.
- OTC analysis based on general understanding of OTC markets and may not be specific to JXFGF.